17 results about "Demyelinating disease" patented technology

The present invention belongs to the field of biomedical technology, and particularly relates to the use of dendritic cells in the prevention and / or treatment of demyelinating diseases. The expression level of Talin1 protein in the dendritic cells is reduced or not expressed. Loading the dendritic cells with myelin peptides can safely and effectively alleviate immune inflammation and nerve damage, and thus is expected to develop into a new therapy for the prevention and / or treatment of demyelinating diseases.

The application belongs to the technical field of medicine, and particularly relates to application of echinacoside in preparation of a medicine for preventing or treating a demyelination disease; the echinacoside can promote differentiation and maturation of OPCs to OLs, promote proliferation of OLs, promote myelin repair, improve pathological changes of myelin ultrastructure, and promote myelin thickness to return to a normal level; the scheme provides a new treatment means for preventing or treating the demyelination disease, and is expected to reverse disability caused by myelin shedding or damage.

To provide a drug having positive effects in subjects suffering from neurological diseases, including neurodegenerative diseases, demyelinating diseases, neuro ischemic diseases and neuromuscular diseases.SOLUTION: Dextran sulfate, or a pharmaceutically acceptable derivative thereof, is used to induce differentiation of glial cells and neurons.SELECTED DRAWING: Figure 12

The disclosure provides methods for (i) treating multiple sclerosis in patient, (ii) treating a patient having symptoms of multiple sclerosis, (iii) preventing the onset of multiple sclerosis symptoms in patient having multiple sclerosis or predisposed to multiple sclerosis; (iv) promoting or enhancing immunomodulation and remyelination and / or myelin repair in a subject in need thereof; (v) a neuroinflammatory disorder; (vi) Amyotrophic Lateral Sclerosis; or (vii) a demyelinating disease or disorder or a hypomyelinating condition, each method comprising administering a therapeutically effective amount of a bryostatin compound to the patient.

Provided herein are compounds and pharmaceutical compositions thereof for inhibiting emopamil binding protein (EBP), and the use of the compounds and pharmaceutical compositions thereof in the treatment of demyelinating diseases, such as multiple sclerosis.

This invention relates to the field of biomedical technology, and provides the application of compound LY2940094 in the preparation of drugs for treating demyelinating diseases of the central nervous system. This invention verifies through modern biological techniques that compound LY2940094 can promote the differentiation of oligodendrocyte precursor cells (OPCs) into mature oligodendrocytes (OLs), thereby promoting the regeneration of myelin in the central nervous system and thus treating demyelinating diseases of the central nervous system.

Disclosed is a protein comprising no more than three human autoantigenic proteins, wherein a first human autoantigenic protein comprises a truncated myelin oligodendrocyte glycoprotein (MOG) amino acid sequence, a second human autoantigenic protein comprises a myelin basic protein (MBP) amino acid sequence, and a third human autoantigenic protein comprises a truncated proteolipid protein (PLP) amino acid sequence. Also disclosed are related nucleic acids, pharmaceutical compositions, methods of treating a demyelinating disease, and methods of producing the proteins.

The present application relates to compounds that are substituted derivatives of 2-(3,5-dichloro-4-(4-hydroxy-benzyl)phenoxy)acetamide and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising one or more of the compounds as an active ingredient, and methods of use thereof, which are useful for treating demyelinating diseases such as multiple sclerosis.

Disclosed is a protein comprising no more than three human autoantigenic proteins, wherein a first human autoantigenic protein comprises a truncated myelin oligodendrocyte glycoprotein (MOG) amino acid sequence, a second human autoantigenic protein comprises a myelin basic protein (MBP) amino acid sequence, and a third human autoantigenic protein comprises a truncated proteolipid protein (PLP) amino acid sequence. Also disclosed are related nucleic acids, pharmaceutical compositions, methods of treating a demyelinating disease, and methods of producing the proteins.

The present invention relates to a combination therapy for treating demyelinating diseases, and more particularly, to a combination therapy of a peptide consisting of an amino acid sequence represented by SEQ ID NO: 1 and intravenous immunoglobulin (IVIg) for treating demyelinating diseases.

The present invention provides a C-terminal MANF fragment with the sequence having length of 34-63 amino acids or a sequence which has at least 80 % sequence identity with the sequence, wherein said fragment is a cell membrane penetrating peptide, for use in the treatment of a demyelinating disease such as multiple sclerosis, wherein said fragment is preferably administered subcutaneously.

The present invention relates to a peptide for treating demyelinating diseases and a use thereof. More specifically, a trimeric peptide according to the present invention has been found to inhibit demyelination and improve myelination, as well as improve nerve damage and symptoms caused by demyelination, in a chronic inflammatory demyelinating polyneuropathy (CIDP) animal model and an acquired peripheral nerve injury animal model. Thus, the peptide according to the present invention can be effectively used as an active ingredient of a composition for preventing or treating demyelinating diseases including CIDP.

The present invention aims to provide a novel component involved in angiogenesis, and a preventive and / or therapeutic agent for neurodegenerative diseases, demyelinating diseases, or cerebrovascular diseases using the same. [Solution] The apelin expression promoter of the present invention is an apelin expression promoter in vascular endothelial cells comprising one or more selected from the group consisting of mesenchymal stem cells, culture supernatant of mesenchymal stem cells, and cellular secretions of mesenchymal stem cells. The preventive and / or therapeutic agent of the present invention is a preventive and / or therapeutic agent for neurodegenerative diseases, demyelinating diseases, or cerebrovascular diseases comprising one or more selected from the group consisting of mesenchymal stem cells, culture supernatant of mesenchymal stem cells, and cellular secretions of mesenchymal stem cells.

Lipids bearing fatty acids with an odd number of carbon atoms can be used as pharmaceuticals or nutritional supplements. In particular, such lipids are used in the treatment and / or prevention of neurodegenerative diseases, optic and retinal degenerative diseases, demyelinating diseases, neuromuscular disorders and muscular dystrophy, brain or spinal cord nerve injury, amyloid related diseases, or other chronic diseases selected from kidney diseases, diabetes, or asthma. The lipids can also be used as a functional food or food supplement for anti-aging or life-span prolongation and brain function improvement for human and / or animals. The herb Ophioglossum can be used for the treatment and / or prevention of said diseases.

The purpose of the present invention is to provide a therapeutic agent for demyelinating diseases in which a culture supernatant of immortalized mesenchymal stem cells into which specific genes are incorporated serves as an active ingredient. Provided is a therapeutic agent for demyelinating diseases in which a culture supernatant of immortalized mesenchymal stem cells into which either the hTERT or pTERT gene and the bmi-1 gene, the HPV-E6 gene, and the HPV-E7 gene are incorporated serves as an active ingredient. The mesenchymal stem cells are preferably of human or porcine origin, and the culture supernatant is preferably obtained by culturing the mesenchymal stem cells for 24-96 hours and contains a component that acts on the receptor c-MET of hepatocyte growth factor (HGF).

The invention discloses application of a GIP receptor agonist in preparation of a medicine for treating demyelination diseases, and belongs to the technical field of biological medicines. The invention provides an application of glucose dependent insulinotropic polypeptide (GIP) or a stable receptor agonist thereof in preparation of drugs for treating demyelinating diseases, wherein the drugs include but are not limited to MS, AIDP, CIDP, neuromyelitis optica pedigree disease (NMOSD) and the like. It is found for the first time that the glucose-dependent insulinotropic polypeptide D-Ala2-GIP can play a remarkable role in protecting and repairing central and peripheral demyelination injuries, and the glucose-dependent insulinotropic polypeptide D-Ala2-GIP has important scientific value and wide clinical application prospects.